Repligen-BioLife merger clears HSR waiting period; stockholder vote set for Oct 5

REPLIGEN CORP

HSR waiting period for Repligen's acquisition of BioLife expired Sept 3, 2026 at 11:59 PM ET.
Deal terms: BioLife shareholders receive $11.25 cash plus 0.1442 Repligen shares per share.
Special BioLife stockholder meeting scheduled Oct 5, 2026 at 9:00 AM ET to vote on merger.
Closing still subject to BioLife stockholder adoption and other customary conditions.
Merger agreement originally signed July 21, 2026; Repligen to acquire all BioLife stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.